natgillin/translations-raw huggingface dataset:
In an European observational registry study which enrolled 319 paediatric patients with chronic kidney disease (13 (4.1%) patients < 1 year of age, 83 (26.0%) patients 1-< 6 years of age, 90 (28.2%) patients 6-< 12 years of age, and 133 (41.7%) patients ≥ 12 years of age) receiving darbepoetin alfa, mean haemoglobin concentrations ranging between 11.3 and 11.5 g/dL and mean weight-adjusted darbepoetin alfa doses remained relatively constant (between 2.31 mcg/kg month and 2.67 mcg/kg month) over the study period for the entire study population. 
U jednom ispitivanju iz europskog opservacijskog registra u koje je bilo uključeno 319 pedijatrijskih bolesnika s kroničnom bubrežnom bolesti (13 (4,1%) bolesnika u dobi < 1 godine, 83 (26,0%) bolesnika u dobi od 1 < 6 godina, 90 (28,2%) bolesnika u dobi od 6 < 12 godina i 133 (41,7%) bolesnika u dobi
The clinical results obtained so far do not indicate any interaction of darbepoetin alfa with other substances. 
4.5 Interakcije s drugim lijekovima i drugi oblici interakcija Dosadašnji rezultati kliničkih ispitivanja nisu pokazali nikakve interakcije darbepoetina alfa s drugim tvarima.
1 single use pre-filled syringe with automatic needle guard. 
1 napunjena štrcaljka s automatskim štitnikom za iglu za jednokratnu uporabu.
For all adult and paediatric patients ≥ 1 year of age with chronic renal failure, Aranesp is given as a single injection, either under your skin (subcutaneous) or into a vein (intravenous). 
Svim odraslim i pedijatrijskim bolesnicima u dobi od 1 godine i starijima s kroničnim zatajenjem bubrega, Aranesp se daje kao jedna injekcija, potkožno (supkutano) ili u venu (intravenski).
Do not remove the cap from the syringe until you are ready to inject. 
Ne uklanjajte poklopac sa štrcaljke prije nego što ste spremni za injiciranje.
Dialysis patients converting from once weekly to once every other week dosing with Aranesp should initially receive a dose equivalent to twice the previous once weekly dose. 
Bolesnici na dijalizi koji prelaze s doziranja lijekom Aranesp jednom tjedno na svaka 2 tjedna trebaju početno primati dozu koja je dvostruko veća od prethodne doze jednom tjedno.
• shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dL (8.7 mmol/L), ESAs are not indicated for use in this patient population. 
• skraćenje vremena do napredovanja tumora u bolesnika s uznapredovalim rakom glave i vrata koji primaju radioterapiju kod primjene radi ciljne koncentracije hemoglobina veće od 14 g/dl (8,7 mmol/l).
Immune system disorders 
Poremećaji imunološkog sustava Vrlo često
In dialysis patients, Aranesp may continue to be administered as a single injection once weekly or once every two weeks. 
U bolesnika na dijalizi može se nastaviti s primjenom lijeka Aranesp kao pojedinačne injekcije jednom tjedno ili jednom svaka 2 tjedna.
The needle cap of the pre-filled syringe contains dry natural rubber (a derivative of latex). 
Pokrov igle napunjene brizgalice sadrži suhu prirodnu gumu (derivat lateksa).
The median TTP based on IRCdetermined PD was 8.0 months in the epoetin alfa plus SOC group and 8.3 months in the SOC group (HR 1.033, 95% CI: 0.924, 1.156). 
Independent Review Committee) iznosio je 8,0 mjeseci u skupini koja je primala epoetin alfa i standardnu zdravstvenu skrb i 8,3 mjeseci u skupini samo sa standardnom zdravstvenom skrbi (HR 1,033; 95% CI: 0,924; 1,156).
• Once your pre-filled pen has been removed from the refrigerator, and left at room temperature (up to 25ºC) for approximately 30 minutes before injection, it must either be used within seven days or disposed of. 
• Nakon što izvadite brizgalicu iz hladnjaka i ostavite je na sobnoj temperaturi (do 25ºC) oko 30 minuta prije injiciranja, brizgalicu je potrebno iskoristiti unutar sedam dana ili baciti.
4 single use pre-filled syringes with automatic needle guards. 
4 napunjene štrcaljke s automatskim štitnikom za iglu za jednokratnu uporabu.
Subject incidence 
Incidencija kod ispitanika
Characteristics (Revision 2, September 2009), frequency of adverse reactions identified in the post-marketing setting was determined using the “Rule of three”. 
(revizija 2, rujan 2009.), učestalost nuspojava uočenih nakon stavljanja lijeka u promet određena je primjenom
If the increase in haemoglobin is inadequate (less than 1 g/dL (0.6 mmol/L) in four weeks) increase the dose by approximately 25%. 
Ako je povećanje hemoglobina nedovoljno (manje od 1 g/dl (0,6 mmol/l) u četiri tjedna), povećajte dozu za otprilike 25%.
The frequency of all hypersensitivity reactions was estimated from clinical trial data as very common in CRF patients. 
Učestalost svih reakcija preosjetljivosti je procijenjena iz podataka kliničkog ispitivanja kao vrlo česta kod bolesnika s kroničnim zatajenjem bubrega.
Aranesp should be administered by the subcutaneous route to patients with anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)) in order to increase haemoglobin to not greater than 12 g/dL (7.5 mmol/L). 
Kod bolesnika s anemijom (primjerice, hemoglobin ≤ 10 g/dl (6,2 mmol/l)) Aranesp treba primjenjivati supkutanim putem da bi se hemoglobin povisio na vrijednost koja nije veća od 12 g/dl (7,5 mmol/l).
For paediatric patients ≥ 1 year of age, in the maintenance phase, Aranesp may continue to be administered as a single injection once weekly or once every two weeks. 
U fazi održavanja, za pedijatrijske bolesnike u dobi od 1 godine i starije, može se nastaviti s primjenom lijeka Aranesp kao pojedinačne injekcije jednom tjedno ili jednom svaka 2 tjedna.
Aranesp is a clear, colourless or slightly pearly solution for injection in a pre-filled syringe. 
Aranesp je bistra, bezbojna ili blago biserna otopina za injekciju u napunjenoj štrcaljki.
Aranesp 25 micrograms solution for injection in vial Aranesp 40 micrograms solution for injection in vial Aranesp 60 micrograms solution for injection in vial Aranesp 100 micrograms solution for injection in vial Aranesp 200 micrograms solution for injection in vial Aranesp 300 micrograms solution for injection in vial darbepoetin alfa 
Aranesp 25 mikrograma otopina za injekciju u bočici Aranesp 40 mikrograma otopina za injekciju u bočici Aranesp 60 mikrograma otopina za injekciju u bočici Aranesp 100 mikrograma otopina za injekciju u bočici Aranesp 200 mikrograma otopina za injekciju u bočici Aranesp 300 mikrograma otopina za injekciju u bočici darbepoetin alfa
PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE-FILLED SYRINGE CARTON WITHOUT TRAY 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA NAPUNJENE ŠTRCALJKE BEZ PODLOŠKA
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (vidjeti Prilog I.: Sažetak opisa svojstava lijeka, dio 4.2).
- Serious skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment. 
- Prijavljene su ozbiljne reakcije na koži, uključujući Stevens-Johnsonov sindrom (SJS) i toksičnu epidermalnu nekrolizu (TEN), povezane s liječenjem epoetinom.
On a clean, well-lit work surface, place the new pre-filled syringe and the other supplies. 
Položite novu napunjenu štrcaljku i ostali pribor na čistu i dobro osvjetljenu radnu površinu.
NAME OF THE MARKETING AUTHORISATION HOLDER Amgen 
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Amgen
• Keep pre-filled syringes out of the sight and reach of children 
• Čuvajte napunjenu štrcaljku izvan pogleda i dosega djece.
Do not use this medicine if you notice the pre-filled syringe contents are cloudy or there are particles in it. 
Ovaj lijek se ne smije primijeniti ako primijetite da je sadržaj napunjene brizgalice mutan ili sadrži vidljive čestice.
c Rash adverse reactions includes PT rash, rash pruritic, rash generalised, rash papular, erythema, exfoliative rash, rash maculo-papular, rash vesicular as well as rash pustular from SOC Infections and Infestations. 
c Nuspojave osipa uključuju sljedeće preporučene pojmove: osip, pruritični osip, generalizirani osip, papularni osip, eritem, eksfolijativni osip, makulopapularni osip, vezikularni osip i pustularni osip iz klasifikacije organskih sustava „Infekcije i infestacije“.
Aranesp (SureClick) is available in packs containing 1 or 4 pre-filled pens. 
Aranesp (SureClick) je dostupan u pakovanjima od 1 ili 4 napunjene brizgalice u blisteru.
Aranesp is supplied ready for use in a vial. 
Aranesp je dostupan spreman za primjenu u bočici.
Syringe label Used syringe barrel 
Etiketa na štrcaljki Iskorišteni spremnik štrcaljke
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment. 
Prijavljene su teške nuspojave na koži (SCARs, engl. severe cutaneous adverse reactions) uključujući Stevens-Johnsonov sindrom (SJS) i toksičnu epidermalnu nekrolizu (TEN), koje mogu biti po život opasne ili smrtonosne, povezane s liječenjem epoetinom.
Aranesp is available in packs of 1 or 4 pre-filled syringes. 
Aranesp je dostupan u pakiranjima od 1 ili 4 napunjene štrcaljke.
Aranesp 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300, 500 micrograms solution for injection in pre-filled pen 
Aranesp 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300, 500 mikrograma otopina za injekciju u napunjenoj brizgalici
Do not store the pre-filled pen in extreme heat or cold. For example, avoid storing in your car glove box or boot. 
Primjerice, izbjegavajte čuvanje brizgalice u pretincu ili prtljažniku Vašeg automobila.
This has been predominantly reported in patients with CRF treated subcutaneously. 
Ovo je predominantno zabilježeno kod bolesnika s kroničnim zatajenjem bubrega liječenih supkutano.
A pharmacokinetic study in patients with chemotherapy-induced anaemia treated with 6.75 mcg/kg darbepoetin alfa administered SC every 
Farmakokinetičko ispitivanje kod bolesnika s anemijom induciranom kemoterapijom liječenih sa 6,75 µg/kg darbepoetina alfa primijenjenog supkutano svaka 3 tjedna u kombinaciji s kemoterapijom, omogućilo je potpuno određivanje terminalnog poluvijeka života.
Uncommon1 
Manje često1
4 single use pre-filled syringes. 
4 napunjene štrcaljke za jednokratnu uporabu.
Aranesp 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300, 500 micrograms solution for injection in pre-filled syringe 
Aranesp 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300, 500 mirograma otopina za injekciju u napunjenoj štrcaljki
Pack size of 1 or 4 pre-filled syringes. 
Veličina pakiranja: 1 ili 4 napunjene brizgalice.
Sodium phosphate monobasic 
Samoprimjena lijeka Aranesp brizgalicom
The initial every other week dose of Aranesp (mcg/every other week) can be determined by dividing the total cumulative dose of r-HuEPO administered over a two-week period by 240. 
Početna doza lijeka Aranesp primijenjena jednom svaka 2 tjedna (μg/svaki drugi tjedan) može se odrediti dijeljenjem ukupne kumulativne doze r-HuEPO primijenjene kroz period od 2 tjedna s 240.
Aranesp is supplied ready for use in a pre-filled pen. 
Aranesp je dostupan spreman za primjenu u napunjenoj brizgalici.
You should contact your doctor, nurse or pharmacist if this does happen. 
Dogodi li se to, morate se obratiti svojem liječniku, medicinskoj sestri ili ljekarniku.
Anaemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a physician's evaluation of the individual patient's clinical course and condition is necessary. 
Simptomi anemije i njene posljedice mogu varirati ovisno o dobi, spolu i sveukupnoj težini bolesti.
SJS/TEN, erythema multiforme, blistering, skin exfoliation 
Stevens-Johnsonov sindrom (SJS)/toksična epidermalna nekroliza (TEN), multiformni eritem, stvaranje mjehura, ljuštenje kože
If the rise in haemoglobin is greater than 2 g/dL (1.25 mmol/L) in four weeks reduce the dose by approximately 25%. 
Ako je porast hemoglobina veći od 2 g/dl (1,25 mmol/l) u četiri tjedna, smanjite dozu za otprilike 25%.
• The grey needle cap is missing or not securely attached. 
• Ukoliko nema sivog pokrova za iglu ili izgleda kao da nije dobro pričvršćen.
Do not shake the pre-filled pen. 
Ne tresite napunjenu brizgalicu.
Dialysis vascular access thrombosisd 
Tromboza u vaskularnom pristupu za dijalizud
4 single use vials 
4 bočice za jednokratnu uporabu
Keep the container in the outer carton in order to protect from light. 
Čuvati spremnik u vanjskom pakiranju radi zaštite od svjetlosti.
The pre-filled syringe contains either 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 or 500 micrograms of darbepoetin alfa. 
Napunjena brizgalica sadrži 10, 15, 20, 30, 40, 50, 60, 80, 100, 130,150, 300, ili 500 mikrograma darbepoetina alfa.
Do not recycle pre-filled syringes or throw them into household waste B Examine the injection site. 
Nemojte reciklirati iskorištene štrcaljke ili ih bacati u kućni otpad.
The initial every other week dose of Aranesp (mcg/every other week) can be determined by dividing the total cumulative dose of r-HuEPO administered over a two-week period by 200. 
Početna doza lijeka Aranesp koja se daje svaka 2 tjedna (μg/svaki drugi tjedan) može se odrediti dijeljenjem ukupne kumulativne doze r-HuEPO-a primijenjene tijekom 2 tjedna s 200.
• The pen contains dry natural rubber, which is made from latex, within the grey cap. Tell your healthcare provider if you are allergic to latex. 
• Brizgalica sadrži osušenu prirodnu gumu, izrađenu od lateksa, u sivom pokrovu.
Aranesp 25 micrograms solution for injection in vial Each vial contains 25 micrograms of darbepoetin alfa in 1 mL (25 mcg/mL). 
Aranesp 25 mikrograma otopina za injekciju u bočici Svaka bočica sadrži 25 mikrograma darbepoetina alfa u 1 ml (25 µg/ml).
Aranesp is a clear, colourless or slightly pearly solution for injection in vial. 
Aranesp je bistra, bezbojna ili blago biserna otopina za injekciju u bočici.
INFORMATION IN BRAILLE Aranesp 130 syringe 
16. PODACI NA BRAILLEOVOM PISMU Aranesp 130 štrcaljka
PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE-FILLED SYRINGE CARTON WITH TRAY 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA S NAPUNJENIM ŠTRCALJKAMA S PODLOŠKOM
Used plunger 
Upotrebljeni klip
If the rise in haemoglobin is greater than 2 g/dL (1.25 mmol/L) in 4 weeks, the dose should be reduced by 25 to 50%. 
Ako je porast hemoglobina veći od 2 g/dl (1,25 mmol/l) u četiri tjedna, dozu se mora smanjiti za 25 do
The initial weekly dose of Aranesp (mcg/week) can be determined by dividing the total weekly dose of r-HuEPO (IU/week) by 200. 
Početna tjedna doza lijeka Aranesp (μg/tjedan) može se odrediti dijeljenjem ukupne tjedne doze r-HuEPO-a (i.j./tjedan) s 200.
Injection site bruising 
Krvarenje na mjestu injiciranja
For all adult and paediatric patients ≥ 1 year of age with chronic renal failure, Aranesp pre-filled pen is given as a single injection, under your skin (subcutaneous). 
Svim odraslim i pedijatrijskim bolesnicima u dobi od 1 godine i starijima s kroničnim zatajenjem bubrega, Aranesp se daje kao jedna injekcija potkožno (supkutano) ili u venu (intravenski).
Upper arm 
Nadlaktica Trbuh
Stroke was reported as common in CRF patients in TREAT (see section 5.1). 
Moždani udar je prijavljen kao čest kod bolesnika s kroničnim zatajenjem bubrega u TREAT (vidjeti dio 5.1).
Do not remove the grey cap from the pre-filled pen until you are ready to inject. 
Nemojte skidati sivi pokrov s napunjene brizgalice sve dok niste spremni injicirati.
In clinical studies, an increased risk of death, serious cardiovascular or cerebrovascular events including stroke, and vascular access thrombosis was observed when ESAs were administered to target a haemoglobin of greater than 12 g/dL (7.5 mmol/L). 
Kod bolesnika s kroničnim zatajenjem bubrega, koncentracija održavanja hemoglobina ne smije prijeći gornju granicu preporučene ciljne koncentracije hemoglobina u dijelu 4.2. U kliničkim ispitivanjima povećani rizik od smrti, ozbiljnih kardiovaskularnih ili cerebrovaskularnih događaja uključujući moždani udar i vaskularnu trombozu na mjestu primjene su primijećeni kada su LSE primjenjivani radi postizanja ciljne koncentracije hemoglobina više od 12 g/dl (7,5 mmol/l).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING VIAL CARTON 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA S BOČICAMA
EU/1/01/185/111 4 Pack 
EU/1/01/185/111 pakiranje od 4
Pack size of 1 or 4 vials. 
Veličina pakiranja: 1 ili 4 bočice.
Aranesp 15 micrograms solution for injection in pre-filled syringe Each pre-filled syringe contains 1.42 mg of sodium in 0.375 mL. 
Aranesp 15 mikrograma otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 1,42 mg natrija u 0,375 ml.
Aranesp 500 micrograms solution for injection in pre-filled syringe Each pre-filled syringe contains 3.79 mg of sodium in 1 mL. 
Aranesp 500 mikrograma otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 3,79 mg natrija u 1 ml.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL WHEN USED WITHOUT TRAY 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA NAPUNJENE ŠTRCALJKE BEZ PODLOŠKA
Do not remove the grey needle cap from the pre-filled syringe until you are ready to inject. 
Ne uklanjajte sivi pokrov s napunjene štrcaljke sve dok niste spremni injicirati.
Aranesp 25 micrograms solution for injection in vial 1 mL solution for injection (25 mcg/mL darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminium seal with flip-off dust cover. 
Aranesp 25 mikrograma otopina za injekciju u bočici 1 ml otopine za injekciju (25 µg/ml darbepoetina alfa) u bočici od stakla tipa 1 s elastomernim čepom laminiranim fluoropolimerom i aluminijskim prstenom s „flip-off“ poklopcem.
The initial weekly paediatric dose of Aranesp (mcg/week) can be determined by dividing the total weekly dose of r-HuEPO (IU/week) by 240. 
Početna tjedna doza lijeka Aranesp (μg/tjedan) za djecu može se odrediti dijeljenjem ukupne tjedne doze r-HuEPO-a (i.j./tjedan) s 240.
c Thromboembolic events adverse reaction includes PT embolism arterial, thrombophlebitis, thrombosis, venous thrombosis limb. 
tromboflebitis, tromboza, venska tromboza ekstremiteta.
INFORMATION IN BRAILLE Aranesp 500 syringe 
16. PODACI NA BRAILLEOVOM PISMU Aranesp 500 štrcaljka
INFORMATION IN BRAILLE Aranesp 80 syringe 
16. PODACI NA BRAILLEOVOM PISMU Aranesp 80 štrcaljka
INFORMATION IN BRAILLE Aranesp 10 syringe 
16. PODACI NA BRAILLEOVOM PISMU Aranesp 10 štrcaljka
Do not touch the injection site before injecting Choose a different site each time you give yourself an injection. 
Birajte svaki put drugo mjesto gdje si dajete injekciju.
STATEMENT OF ACTIVE SUBSTANCE(S) Each 1 mL vial contains 25 micrograms darbepoetin alfa. 
NAVOĐENJE DJELATNE(IH) TVARI Jedna bočica od 1 ml sadrži 25 mikrograma darbepoetina alfa.
INFORMATION IN BRAILLE Aranesp 15 syringe 
16. PODACI NA BRAILLEOVOM PISMU Aranesp 15 štrcaljka
INFORMATION IN BRAILLE Aranesp 20 syringe 
16. PODACI NA BRAILLEOVOM PISMU Aranesp 20 štrcaljka
Aranesp 15 micrograms solution for injection in pre-filled syringe Each pre-filled syringe contains 15 micrograms of darbepoetin alfa in 0.375 mL (40 mcg/mL). 
Aranesp 15 mikrograma otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 15 mikrograma darbepoetina alfa u 0,375 ml (40 μg/ml).
Aranesp 130 micrograms solution for injection pre-filled pen EU/1/01/185/072 - 1 pack 
Aranesp 130 mikrograma otopina za injekciju u napunjenoj brizgalici EU/1/01/185/072 - pakiranje od 1
Aranesp 20 micrograms solution for injection pre-filled pen EU/1/01/185/047 - 1 pack 
Aranesp 20 mikrograma otopina za injekciju u napunjenoj brizgalici EU/1/01/185/047 - pakiranje od 1
INFORMATION IN BRAILLE Aranesp 150 syringe 
16. PODACI NA BRAILLEOVOM PISMU Aranesp 150 brizgalica
Aranesp 300 micrograms solution for injection in pre-filled syringe Each pre-filled syringe contains 2.27 mg of sodium in 0.6 mL. 
Aranesp 300 mikrograma otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 2,27 mg natrija u 0,6 ml.
If the rise in haemoglobin is greater than 2 g/dL (1.25 mmol/L) in four weeks reduce the dose by approximately 25%, depending on the rate of increase. 
Ako je porast hemoglobina veći od 2 g/dl (1,25 mmol/l) u četiri tjedna, smanjite dozu za otprilike 25%, ovisno o brzini porasta hemoglobina.
Aranesp 200 micrograms solution for injection in vial Each vial contains 200 micrograms of darbepoetin alfa in 1 mL (200 mcg/mL). 
Aranesp 200 mikrograma otopina za injekciju u bočici Svaka bočica sadrži 200 mikrograma darbepoetina alfa u 1 ml (200 µg/ml).
d Oedema: includes PT Oedema Peripheral, Oedema, Generalised Oedema, Oedema due to Cardiac Disease, Face oedema e Injection site pain adverse reaction includes PT injection site pain, administration site pain, catheter site pain, infusion site pain and vessel puncture site pain. 
e Nuspojava bol na mjestu injiciranja uključuje sljedeće preporučene pojmove: bol na mjestu injiciranja, bol na mjestu primjene, bol na mjestu katetera, bol na mjestu infuzije i bol na mjestu punkcije vene.
Aranesp 25 micrograms solution for injection in vial. 
Aranesp 25 mikrograma otopina za injekciju u bočici.
Aranesp 100 micrograms solution for injection in vial Each vial contains 100 micrograms of darbepoetin alfa in 1 mL (100 mcg/mL). 
Aranesp 100 mikrograma otopina za injekciju u bočici Svaka bočica sadrži 100 mikrograma darbepoetina alfa u 1 ml (100 µg/ml).
Do not use this medicine after the expiry date which is stated on the carton and on the pre-filled syringe label after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i naljepnici napunjene štrcaljke iza „Rok valjanosti“/EXP.
Aranesp 60 micrograms solution for injection in vial Each vial contains 60 micrograms of darbepoetin alfa in 1 mL (60 mcg/mL). 
Aranesp 60 mikrograma otopina za injekciju u bočici Svaka bočica sadrži 60 mikrograma darbepoetina alfa u 1 ml (60 µg/ml).
It is normal to see a drop of liquid at the end of the needle or yellow safety guard. 
Na vrhu igle ili žutog sigurnosnog štitnika može se naći kap tekućine, što je normalno.
Aranesp 15 micrograms solution for injection in pre-filled pen Each pre-filled pen contains 15 micrograms of darbepoetin alfa in 0.375 mL (40 mcg/mL). 
Aranesp 15 mikrograma otopina za injekciju u napunjenoj brizgalici Jedna napunjena brizgalica sadrži 15 mikrograma darbepoetina alfa u 0,375 ml (40 µg/ml).
EU/1/01/185/107 4 Pack 
EU/1/01/185/107 pakiranje od 4
Aranesp 300 micrograms solution for injection pre-filled pen EU/1/01/185/055 - 1 pack 
Aranesp 300 mikrograma otopina za injekciju u napunjenoj brizgalici EU/1/01/185/055 - pakiranje od 1
EU/1/01/185/032 4 Pack Blister 
EU/1/01/185/032 pakiranje od 4
Aranesp 200 micrograms solution for injection vial EU/1/01/185/108 1 Pack 
Aranesp 200 mikrograma otopina za injekciju u bočici EU/1/01/185/108 pakiranje od 1
INFORMATION IN BRAILLE Aranesp 40 syringe 
16. PODACI NA BRAILLEOVOM PISMU Aranesp 40 štrcaljka
Aranesp 500 micrograms solution for injection in pre-filled pen Each pre-filled pen contains 3.79 mg of sodium in 1 mL. 
Aranesp 500 mikrograma otopina za injekciju u napunjenoj brizgalici Jedna napunjena brizgalica sadrži 3,79 mg natrija u 1 ml.
Keep the pre-filled syringe in the outer carton in order to protect from light. 
Čuvati napunjenu štrcaljku u vanjskom pakiranju radi zaštite od svjetlosti.
Aranesp 40 micrograms solution for injection pre-filled pen EU/1/01/185/049 - 1 pack 
Aranesp 40 mikrograma otopina za injekciju u napunjenoj brizgalici EU/1/01/185/049 - pakiranje od 1
Rash/erythemae 
Osip/eriteme
MARKETING AUTHORISATION NUMBER(S) EU/1/01/185/071 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/01/185/071
Aranesp 15 micrograms solution for injection in pre-filled pen Each pre-filled pen contains 1.42 mg of sodium in 0.375 mL. 
Aranesp 15 mikrograma otopina za injekciju u napunjenoj brizgalici Jedna napunjena brizgalica sadrži 1,42 mg natrija u 0,375 ml.